is tirzepatide going off the market Trends, Share and Forecast, 2026-2033 Grey market tirzepatide: what you

Heres whats on the CBC Health Units watch list for 2026: New approaches to connecting people with family doctors, anticipated changes to cancer screening, misinformation and vaccine wariness, future uses for GLP-1 agonists (like Ozempic and Wegovy) and the morphing toxic drug crisis.

Methods PIONEER REAL Switzerland was a 3444-week, multicentre, prospective, non-interventional, single-arm study of adults with T2D nave to injectable glucose-lowering medication who were initiated on oral semaglutide in routine clinical practice

Colleen McCabe, PharmD, BCOP, and Lindsay Mundy, PharmD, BCOP, provided an engaging exploration of the benefits and potential pitfalls seen with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in an oncology setting

Trulicity vs Mounjaro: compare weight loss results, side effects, dosage, and costs

More than one million Australians have been dispensed a GLP-1 receptor agonist over the past five years, fuelling the emergence []

URPS Grand Est